BRIEF published on 06/10/2026 at 20:18, 4 months 20 days ago Poxel nomme Yves Decadt PDG pour faire progresser ses objectifs stratégiques Partenariats Stratégiques Biopharmaceutique Poxel Iméglimine Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 4 months 20 days ago Poxel nomme Yves Decadt comme nouveau Directeur Général Partenariats Stratégiques Biopharmaceutique Plan De Continuation Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 4 months 20 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 4 months 20 days ago Informations privilégiées / Autres communiqués Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques. Continuité et ambition commerciale confirmée Partenariats Poxel PXL065 Iméglimine Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 7 months ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 7 months ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 7 months ago Poxel cède le PXL770 à Scynexis pour une valeur potentielle de 196 millions de dollars Accord Financier Poxel PXL770 SCYNEXIS Polykystose Rénale
BRIEF published on 03/31/2026 at 13:12, 7 months ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
PRESS RELEASE published on 03/31/2026 at 13:07, 7 months ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 7 months ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) Poxel annonce la cession du PXL770 à Scynexis pour jusqu'à 196 millions de dollars, renforçant sa position financière. Étude clinique phase 2 prévue pour ADPKD. Accord financier détaillé Cession Accord Financier Poxel PXL770 SCYNEXIS
Published on 10/30/2026 at 23:35, 14 hours 3 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 14 hours 8 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 16 hours 51 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 18 hours 38 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 22 hours 8 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 14 hours 49 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 18 hours 59 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 14 hours 38 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 14 hours 38 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
